Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly 
Observed Therapy to Look at Potential Interactions Between Truvada 
and Hormone Therapy  
 
[STUDY_ID_REMOVED]  
 
Document Date: March 15, 2018  
 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 1 of 45
Protocol Template Effective: 07 JAN 2015 I-BrEATHe - Interactions BEtween Antiretrovirals And Transgender 
Hormones:
A Pharmacokinetic sub study of the TRIUMPH study
Protocol 
Number:N/A
Version Date: 1.3 – 15-March-[ADDRESS_90476]:N/A
IND Number: N/A
Development Phase:FDA approved
Sponsor: Robert M. Grant, MD, MPH 
[ADDRESS_90477], San Francisco, CA [ZIP_CODE]
Funding 
Organization:University of [LOCATION_004] Office of the President, via the [LOCATION_004] HIV/AIDS Research Program (UCOP via CHRP)
Principal Investigator:[CONTACT_5627]: Robert M Grant 
Telephone: 415-350-8909E-mail: [EMAIL_1640] 
Co -Principal 
Investigator:[CONTACT_5627]: Madeline B. Deutsch 
Telephone: 415-797-7136E-mail: [EMAIL_1641] 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 2 of 45
Protocol Template Effective: 07 JAN 2015 Approval:
PI/Sponsor Signature (Name [CONTACT_13693]) Date
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 3 of 45
Protocol Template Effective: [ADDRESS_90478] a need to know, with the obligation not to further disseminate this information.  
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 4 of 45
Protocol Template Effective: [ADDRESS_90479] read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety of the study participants enrolled under my supervision and providing Drs. Robert Grant and Madeline Deutsch with complete and timely information, as outlined in the protocol.  It is understood that all information pertaining to the study will be held strictly confidential and that this confidentiality requirement applies to all study staff at this site. Furthermore, on behalf of the study staff and myself, I agree to maintain the procedures required to carry out the study in accordance with accepted GCP principles and to abide by [CONTACT_38114].
Protocol Number :  N/A
Protocol Title : I-BrEATHe - Interactions BEtween Antiretrovirals And Transgender 
Hormones.
Protocol Date :  22Mar2017
Investigator Signature [CONTACT_82993] # N/A
Site Name [CONTACT_82994] [ADDRESS_90480]
San Francisco, CA [ZIP_CODE]
Phone Number
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 5 of 45
Protocol Template Effective: [ADDRESS_90481] ...................................................................................14
2 BACKGROUND ............................................................................................................15
2.1 O VERVIEW OF NON-CLINICAL STUDIES ........................................................................16
2.2 O VERVIEW OF CLINICAL STUDIES .................................................................................16
3 STUDY RATIONALE ...................................................................................................16
3.1 R ISK / BENEFIT ASSESSMENT ........................................................................................17
4 STUDY OBJECTIVES ..................................................................................................18
4.1 P RIMARY OBJECTIVE ..................................................... ................................................18
4.2 S ECONDARY OBJECTIVES ...................................................... ................................................18
5 STUDY DESIGN.................................................................................................................1 8
5.1 S TUDY OVERVIEW ........................................................ ......................................................18
5.2 P HARMACOGENETIC TESTING ................................................ ...............................................19
6 CRITERIA FOR EVALUATION ..................................................................................19
6.1 P RIMARY ENDPOINT ..................................................... .................................................19
6.2 S ECONDARY ENDPOINTS ................................................ ...............................................19
6.3 S AFETY EVALUATIONS ................................................... ...............................................19
7 PARTICIPANT SELECTION .......................................................................................19
7.1 S TUDY POPULATION ..................................................... .................................................19
7.2 I NCLUSION CRITERIA : ...................................................... ....................................................19
7.3 EXCLUSION CRITERIA ................................................... .................................................20
7.4 E LIGIBILITY DETERMINATION ........................................................................................20
7.5 R ECRUITMENT AND RETENTION .....................................................................................21
7.5.1 Study site ........................................................... ........................................................21
7.5.2 Recruitment ........................................................... ....................................................21
7.5.3 Retention ........................................................... ........................................................22
8 CONCURRENT MEDICATIONS .................................................................................22
8.1 A LLOWED MEDICATIONS AND TREATMENTS ...........................................................................22
8.2 P ROHIBITED MEDICATIONS AND TREATMENTS ........................................................................22
9 STUDY TREATMENT ..................................................................................................23
9.1 M ETHOD OF ASSIGNING PARTICIPANTS TO TREATMENT GROUPS ................................23
9.2 FTC/TDF ............................................................. ..........................................................23
9.2.1 FTC/TDF Formulation ................................................ ..............................................23
9.2.2 FTC/TDF and pregnancy ............................................... ...........................................23
9.2.3 Packaging and Labeling .............................................. ..............................................23
9.3 S UPPLY OF STUDY DRUG AT THE SITE.....................................................................................23
9.3.1 Storage .............................................................. ........................................................24
9.4 D ISPENSATION OF STUDY DRUG AT THE SITE...............................................................24
9.4.1 Dosage/Dosage Regimen ............................................... ...........................................24
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 6 of 45
Protocol Template Effective: [ADDRESS_90482] ..................................................... ..................................................27
10.2 C LINICAL LABORATORY MEASUREMENTS ....................................................................27
10.2.1 Blood Chemistry Profile ............................................ ............................................27
10.2.2 Kidney function Profile .............................................. ...........................................27
10.2.3 Hormonal Therapy Profile ....................................................................................27
10.2.4 Serology testing ................................................... ..................................................27
10.2.5 HIV infection testing ............................................... ..............................................27
10.2.6 Off protocol testing ................................................. ..............................................27
10.3 R ESEARCH LABORATORY MEASUREMENTS ..................................................................28
10.3.1 Pharmacokinetic Measurements ..................... .....................................................28
10.3.2 Hormonal Therapy Profile ............................ .........................................................28
10.3.3 Genetic testing ......................................... .............................................................28
10.4 V IDEO DOSING ASSESSMENTS .......................................................................................28
11 EVALUATIONS BY [CONTACT_16990]....................................................................................................29
11.1 P HONE OR REFERRING CLINIC PRE SCREENING ..............................................................29
11.2 V ISIT 1 (SCREENING VISIT )................................................ ............................................29
11.3 V ISIT 2 (WEEK 0 OR ENROLMENT , WITHIN 28 DAYS OF SCREENING )..............................29
11.4 V ISIT 3 (WEEK 1, 2 AND 3, VISIT WINDOW PLUS OR MINUS 2 DAYS )..............................30
11.5 V ISIT 4 (WEEK 4 OR END OF STUDY , VISIT WINDOW PLUS OR MINUS 2 DAYS )...............30
11.6 E ARLY WITHDRAWAL VISIT............................................... ...........................................30
12 ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION ........................31
12.1 A DVERSE EVENTS ........................................................ ..................................................31
12.2 S ERIOUS ADVERSE EXPERIENCES (SAE) .......................................................................32
12.2.1 Serious Adverse Experience Reporting .................................................................33
12.2.2 Suicidal ideation ................................................... ................................................33
12.3 M EDICAL MONITORING ................................................. ................................................33
13 DISCONTINUATION AND REPLACEMENT OF PARTICIPANTS .........................33
13.1 E ARLY DISCONTINUATION OF STUDY DRUG .................................................................33
12.3 W ITHDRAWAL OF PARTICIPANTS FROM THE STUDY ..................................................................34
12.4 R EPLACEMENT OF PARTICIPANTS ............................................... ...........................................34
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 7 of 45
Protocol Template Effective: 07 JAN 2015 14 PROTOCOL VIOLATIONS .........................................................................................34
15 STATISTICAL METHODS AND CONSIDERATIONS ..............................................35
15.1 D ATA SETS ANALYZED .................................................. ................................................35
15.2 D EMOGRAPHIC AND BASELINE CHARACTERISTICS .......................................................35
15.3 A NALYSIS OF PRIMARY ENDPOINT ................................................................................35
15.4 S AMPLE SIZE........................................................... .......................................................35
16 DATA COLLECTION, RETENTION AND MONITORING .......................................36
16.1 D ATA COLLECTION INSTRUMENTS ................................................................................36
16.2 D ATA MANAGEMENT PROCEDURES ..............................................................................36
16.3 D ATA QUALITY CONTROL AND REPORTING ..................................................................36
16.4 A RCHIVAL OF DATA .................................................... ..................................................36
16.5 A VAILABILITY AND RETENTION OF INVESTIGATIONAL RECORDS ................................37
16.6 M ONITORING ......................................................... ........................................................37
16.7 P ARTICIPANT CONFIDENTIALITY ...................................................................................37
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS ...................37
17.1 P ROTOCOL AMENDMENTS ................................................ .............................................38
17.2 I NSTITUTIONAL REVIEW BOARDS AND INDEPENDENT ETHICS COMMITTEES ...............38
17.3 I NFORMED CONSENT FORM ............................................... ............................................38
17.4 P UBLICATIONS ......................................................... ......................................................39
17.5 I NVESTIGATOR RESPONSIBILITIES .................................................................................39
18 REFERENCES ..............................................................................................................42
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 8 of 45
Protocol Template Effective: [ADDRESS_90483]
FDA Food and Drug Administration
FTC Emtricitabine
FTC/TDF Emtricitabine/ Tenofovir disoproxil fumarate
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act of [ADDRESS_90484] upper limit of normal
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 9 of 45
Protocol Template Effective: 07 JAN 2015 PROTOCOL SYNOPSIS
TITLE I-BrEATHe - Interactions BEtween Antiretrovirals And Transgender 
Hormones.
SPONSOR Robert M. Grant and  Madeline B. Deutsch
FUNDING 
ORGANIZATIONUniversity of [LOCATION_004] Office of the President via the [LOCATION_004] HIV/AIDS Research Program
NUMBER OF SITES 1
RATIONALE Drug concentrations after receipt of oral Truvada Pre Exposure Prophylaxis (or PrEP) appeared to be lower in transgender women compared to Men who Have Sex with Men (MSM) in the iPrEx study. Reasons for the lower drug concentrations may be behavioral or biomedical, or a combination of both. There are few to no studies which investigate the potential drug to drug interactions between the components of Truvada (emtricitabine or FTC and tenofovir disproxil fumarate or TDF) and feminizing hormones. In addition, no PrEP studies have ever included transgender men; therefore no knowledge exists on the potential interactions between FTC/TDF and masculinizing hormones. 
The pharmacokinetic study, using directly observed therapy (DOT), is 
designed to address the question whether feminizing or masculinizing hormones affect FTC/TDF levels in transgender women or transgender men respectively.
STUDY DESIGN This is a pharmacokinetic study
PRIMARY OBJECTIVEAssess pharmacokinetic drug-drug interactions between tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and cross-sex hormone therapy.
SECONDARY OBJECTIVESAssess Adverse Events related to TDF/FTC in transgender men and women and compare to historical controls in non trangender MSM
NUMBER OF PARTICIPANTS48 (24 transgender women and 24 transgender men)
PARTICIPANT SELECTION
CRITERIAInclusion Criteria: 
All subjects:
•HIV antibody seronegative (negative HIV rapid test),
•18 years or older,
•Has a smart phone with access to two-way video call 
capability,
•Willingness to be contact[CONTACT_5365] a short call every day for 4 
weeks,
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 10 of 45
Protocol Template Effective: 07 JAN 2015 •Adequate renal function (creatinine clearance ≥ 60 ml/min 
estimated by [CONTACT_82961]), 
•Provides written informed consent,
For Transgender women:
•Assigned male sex at birth, and self-reported current gender 
identity as “woman” or “transgender women”, or other trans-
feminine spectrum identity, 
•Current feminizing Hormone Therapy (HT) use for at least 6 
months
For Transgender men:
•Assigned female sex at birth, and self-reported current gender 
identity as “man” or “transgender man”, or other trans-masculine spectrum identity,
•Current masculinizing Hormone Therapy (HT) use for at least 
6 months with testosterone.
Exclusion Criteria:
•Expects to change or discontinue current HT use during the 4 
weeks study period,
•Signs of symptoms of acute viral syndrome,
•Use of FTC or TDF in the past 90 days
•Receiving ongoing therapy with any of the following: ART, 
including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents, interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, systemic chemotherapeutic agents, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agents
•Renal insufficiency documented as Creatinine Clearance < 60 
ml/min
•For masculine-spectrum identifying persons, positive 
pregnancy test at screening
•At enrollment, has any other condition that, based on the 
opi[INVESTIGATOR_66678], would preclude provision of informed consent; make participation in the study 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 11 of 45
Protocol Template Effective: 07 JAN 2015 unsafe; complicate interpretation of study outcome data; or 
otherwise interfere with achieving the study objectives.
TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATIONFDA approved Truvada (one tablet containing 200 mg of emtricitabine or FTC and 300 mg of tenofovir disoproxil fumarate or TDF) once daily taken orally with or without food. [COMPANY_009] Sciences will dispense medication to through their FDA approved commercial packaging of [ADDRESS_90485], DOSE AND ROUTE OF ADMINISTRATIONN/A
DURATION OF PARTICIPANT PARTICIPATION AND DURATION OF STUDYParticipants will be on study for up to 56 days
Screening:  up to 28 daysTreatment:  4 weeks or 28 days (participants come to clinic weekly 
and DOT via video calls)
Follow-up:  n/aThe total duration of the study is expected to be 7-9 months:  1-3 
months for participant recruitment and 6 for final participant follow-up.
CONCOMMITANT MEDICATIONSAllowed:
Testosterone, estradiol, spi[INVESTIGATOR_8407], Prohibited: ART, including nucleoside analogs, non-nucleoside reverse 
transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents, interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, systemic chemotherapeutic agents, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agents
EFFICACY EVALUATIONSN/A
PRIMARY ENDPOINT Concentrations of FTC triphosphate and tenofovir diphosphate (TFV-DP) in Dried Blood Spots (DBS)
SECONDARY ENDPOINTSN/A
OTHER EVALUATIONSN/A
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 12 of 45
Protocol Template Effective: 07 JAN 2015 SAFETY 
EVALUATIONSIncidence of adverse events (AEs will be collected as part of the 
weekly visit if participants report AEs)
PLANNED INTERIM ANALYSES N/A
STATISTICS
Primary Analysis PlanWe will compare levels of Tenofovir DiPhosphate (TFV-DP), the 
phosphorylated active tenofovir molecule in dried blood spots and rates of adverse events between trans men and trans women and a group of MSM historical controls from the iPrEx OLE study.  We will compare log transformed TFV-DP levels using  a linear mixed effects model with factors for group (trans men v. trans women v. MSM) and times (1, 2, 3 and 4 weeks after initiation) and their interaction with an unstructured covariance across visits and test for differences at between groups at each time point. If values appear to violate the normal distribution, we will obtain p-values and confidence intervals using the bootstrap. All p-values will be two-sided with p-value < 0.[ADDRESS_90486].
Rationale for Number of ParticipantsA sample size of 48 (24 trans women and 24 trans men) allows detection of a difference of 0.52 log difference (1.68 fold difference) in TFV-DP from dried blood spots with 81% power on a two-sided 0.[ADDRESS_90487] at any time point between our trans participants and MSM historical controls. A difference of 0.70 log (2.0 fold difference) can be detected between either group (trans men or women), and MSM historical controls with 80% power on a two-sided 0.[ADDRESS_90488].
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 13 of 45
Protocol Template Effective: 07 JAN 2015 1 PROTOCOL TEAM AND SITE
1.1 Protocol Team Roster
University of [LOCATION_004], San Francisco
Robert Grant, MD, MPH
Principal Investigator[INVESTIGATOR_82943], School of MedicineUniversity of [LOCATION_004], San Francisco1001 Potrero AvenueSan Francisco, CA [ZIP_CODE] [EMAIL_1642]
Phone: 415-3508909Fax: [PHONE_1929]
Madeline Deutsch, MD, MPH
Co-principal investigator[INVESTIGATOR_82944], San Francisco2356 Sutter St, 3
rd Floor
San Francisco, CA [ZIP_CODE] [EMAIL_1643]
Phone: [PHONE_1930]
David Glidden, PhD
Co-Investigator (Statistics)Department of Epi[INVESTIGATOR_82945], San Francisco185 Berry Street, Suite 5700San Francisco, CA [ZIP_CODE] [EMAIL_1644]
Phone: 1-415-514-8009Fax: [PHONE_1931]
Jae Sevelius, PhD
Co-investigatorDepartment of MedicineSchool of Medicine
University of [LOCATION_004], San Francisco
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 14 of 45
Protocol Template Effective: 07 JAN 2015 San Francisco, CA [ZIP_CODE] [LOCATION_003]
[EMAIL_1645]
Phone: 1- [PHONE_1932]
Patricia Defechereux, PhD
Pulmonary and Critical Care, School of MedicineUniversity of [LOCATION_004], San Francisco1001 Potrero AvenueSan Francisco, CA [ZIP_CODE] [EMAIL_1646]
Phone: 1-415-734-4811Fax: [PHONE_1929]
San Francisco AIDS Foundation
Marion Pellegrini, 
[ADDRESS_90489], San Francisco, [LOCATION_004], [EMAIL_1647]: [PHONE_1933]
Bringham And Women’s Hospi[INVESTIGATOR_82946], MD, PhD
Co-investigatorBrigham and Womens Hospi[INVESTIGATOR_82947] - RFB [ADDRESS_90490] [LOCATION_011] MA [EMAIL_1648]
Phone: [PHONE_1934]
1.[ADDRESS_90491] San Francisco, CA [ZIP_CODE] [LOCATION_003]Phone: 1-415-487-8000Fax: [PHONE_1935]
1.[ADDRESS_90492] Diagnostics
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 15 of 45
Protocol Template Effective: 07 JAN 2015 Director: Salim Kabawat, MD
[ADDRESS_90493], Cambridge, MA  [ZIP_CODE] [EMAIL_1649]
Phone: 1-617-547-8900Fax: [PHONE_1936]
Quest Diagnostics Inc.
Director: [CONTACT_82995] L. Kerschmann967 Mabury Rd, San Jose, CA [ZIP_CODE] [EMAIL_1650]
Phone: 1- [PHONE_1937] Fax: [PHONE_1938]
ARI/UCSF Virology Laboratory 
Director: Robert M. Grant, MD, MPHSan Francisco General Hospi[INVESTIGATOR_307]1001 Potrero St., Building 100, Room 104San Francisco, CA [ZIP_CODE] [EMAIL_1642]
Phone: 1-415-734-4810Fax: [PHONE_1939]
LabCorp
[ADDRESS_90494]. So STE 200San Diego, CA [ZIP_CODE]-4108Phone: [PHONE_1940]
TBN as needed to support study site
1.4 Research Laboratories
Colorado AntiViral Pharmacology Laboratory
Director: [CONTACT_82996], PhDUC Denver-Skaggs School of Pharmacy and Pharmaceutical SciencesV20-441012850 E Montview BlvdAurora, CO [ZIP_CODE]
[EMAIL_1651]
Phone: 1-303-724-6132Fax: [PHONE_1941]
Brigham Research Assay Core
Director: [CONTACT_82997], MD PhD
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 16 of 45
Protocol Template Effective: [ADDRESS_90495]
RFB Room 477[LOCATION_011], MA [ZIP_CODE]
Phone: [EMAIL_1652]
TBN as needed to support study site
1.[ADDRESS_90496]., Ste. 315University of [LOCATION_004]San Francisco, CA [ZIP_CODE] [EMAIL_1653]
Campus Mailbox: 0962General Office: 1-415-476-1814Fax: [PHONE_1942]
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 17 of 45
Protocol Template Effective: 07 JAN 2015 2 BACKGROUND
The TRIUMPH study, or trans Research-Informed communities United in the 
Mobilization for the Prevention of HIV, is a new study responding to a pressing need for culturally-relevant community-led pre-exposure prophylaxis (PrEP) programs for transgender communities, especially for trans women of color who are most affected by [CONTACT_36160][INVESTIGATOR_901]. The TRIUMPH study will strive to identify the most effective PrEP service provision strategies which take into account the particular facilitators and barriers that transgender communities encounter in the health care system. To date, transgender women included in HIV prevention studies have been lumped into the larger aggregate of Men who have sex with Men (MSM) without taking into account the unique sociocultural context of transgender women. The TRIUMPH study will also include transgender men and other members of various transgender communities. The TRIUMPH project’s goal is to identify the best methods to deliver PrEP safely and effectively to transgender communities while achieving the highest levels of adherence possible.
PrEP is the newest and most promising biomedical HIV prevention intervention yet 
developed and tested. The first clinical trial of PrEP (‘iPrEx’ or iniciativa Profilaxis Pre-Exposición) included MSM and transgender women who were at higher risk for HIV infection, and found that daily oral Truvada PrEP reduced the risk of HIV acquisition by 44% on an intention to treat basis [1].  However, a sub-analysis of the iPrEx data conducted by [CONTACT_82962] , found zero effectiveness on an intention to treat basis among 
the small subgroup of transwomen in the study [2]. Further analyses revealed that the subgroup of trans women in iPrEx who were using hormones were less likely to have protective drug levels than those trans women not on hormones (OR 0.14, p<0.001). It is unclear if this difference is behavioral (less drug uptake) or biomedical (drug-drug interactions) in nature, or due to some combination of these factors, given the lack of pharmacokinetic (PK) studies testing for interactions between cross-sex hormone therapy (HT) and TDF/FTC, the active ingredients of Truvada. While there are studies of systemic drug-drug interactions between oral contraceptives and TDF, no such studies have been done with FTC, and no studies have been done with gender affirming HT, which differs from hormonal contraception in several respects. Drug-drug interactions with bioidentical 17-beta estradiol used for gender affirming hormone therapy among transgender women have not been studied.
The Interactions BEtween Antiretrovirals And Transgender Hormones, or I-BrEATHe 
study, described in this protocol is a sub study of the TRIUMPH study. I-BrEATHe will address one of the secondary aims of the TRIUMPH study which is to assess the pharmacokinetic drug-drug interactions between cross-sex HT and daily oral FTC/TDF. 
Given that there are no PrEP studies to date that have specifically enrolled trans identified 
men, or have looked at the interactions between masculinizing HT and FTC/TDF, I-BrEATHe will enroll both transgender women and men. Transgender men report sexual rapports without condoms both vaginally and anally (range 26-60%), exhibit patterns of STIs transmission and unwanted pregnancies. Transgender men also report use of sex for gender affirmation. Small convenience samples show that HIV prevalence is between 2- 5% [3, 4]. To date, there are no programs or PrEP recommendations specific for transgender men.
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 18 of 45
Protocol Template Effective: 07 JAN 2015 2.1 Overview of Non-Clinical Studies
N/A
2.[ADDRESS_90497] that TDF/FTC interacts with commonly used feminizing or masculinizing hormone regimens, and evidence from studies of ARV interactions with hormonal contraceptives have been reassuring, no direct study of these interactions has been conducted to date. 
Our team led the only trans-specific sub analysis to date of the iPrEx randomized 
controlled trial (RCT) data as well as the open label extension (OLE) study, which included periodic dried blood spot (DBS) drug level monitoring [2]. In iPrEx, gender identity data was not collected using current best practices (“two-step” method [5]), making the identification of transgender participants in this multinational, multicultural and multilingual trial difficult. As all iPrEx participants had been assigned male sex at birth, a transgender subgroup of 339/2499 participants (14% of overall sample) was constructed comprised of the 29 (1%) who identified as women, 296 (12%) who identified as “trans”, and 14 (1%) who reported use of feminizing hormones. None had undergone gender affirming genital surgery. Compared with MSM, transgender women more frequently reported transactional sex, receptive anal intercourse without a condom, or more than [ADDRESS_90498] (OR=0.39, 95% CI = 0.16 to 0.96, p=0.04). While there was no effectiveness of PrEP for transgender women on an intention-to-treat basis, none of the transgender participants who seroconverted had detectible drug levels at the time of HIV diagnosis. In comparison to MSM in the OLE, transgender participants had less time with protective drug concentrations (17% vs 35%, p<0.001) and were less likely to have concentrations indicating > 3 tablets/week (OR 0.71, 95% CI 0.49 to 1.03, p=0.07). Of the two transgender women who seroconverted during the OLE, both had drug levels below 350 fmol/punch in DBS, the level associated use of 2 tablets per week at the time of seroconversion. The lower concentrations were more likely if the transgender women used feminizing hormones.
Of the 7 clinical trials of Truvada PrEP for HIV prevention conducted to date, iPrEx is the 
only one with confirmed enrollment of trans women [6]. No clinical studies or demonstration projects were conducted with transgender men. 
For more detail regarding PrEP clinical trials, please refer to the Prescribing information 
for Truvada.
[ADDRESS_90499] that concentrations of FTC/TDF were especially low among transgender women 
reporting use of feminizing hormones in the iPrEx study, which may reflect less PrEP use or a drug-drug interaction, is of high interest given that concerns about the impact of PrEP 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 19 of 45
Protocol Template Effective: 07 JAN 2015 on gender affirming hormone therapy is the main barrier for uptake of PrEP among 
transgender women [7] . While transgender men as a group have also been shown to be at 
elevated risk for HIV infection [4, 8], no information about PrEP use and drug levels is available for transgender men since they have never been formally included in PrEP research. Therefore, there are no data on the potential effects of testosterone on FTC/TDF drug concentrations. FTC/TDF drug concentrations have emerged as strong correlates of protection in PrEP trials, accounting for the majority of the variation in PrEP benefits across trials and across individual participants in trials. For example, while oral FTC/TDF PrEP had 44% efficacy on an intention to treat basis in iPrEx, the protective effect was more than 90% among those with detectable drug and negligible among those with no detectable drug in blood [1, 9].
The pharmacokinetic study of PrEP metabolites concentrations in association with 
feminizing and masculinizing hormones using directly observed therapy (DOT) will allow to establish whether interactions exist between these drugs. I-BrEATHe also provides an opportunity to include transgender men in PrEP research. Though transgender men are likely to be at lower risk for HIV acquisition than transgender women, the lack of available data regarding use of PrEP in transgender men must be remediated. I-BrEATHe will recruit equal numbers of transgender women who are using estradiol plus spi[INVESTIGATOR_8407] (the most common HT regimen) and transgender men who are using testosterone. The primary aim will be to measure the intracellular active metabolites of TDF/FTC, tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP), levels in DBS collected after 1, 2, 3, and 4 weeks of video-observed Truvada for PrEP daily dosing, and comparing drug levels in the two groups receiving HT to previously acquired DBS drug levels data in MSM [9-11].
3.1 Risk / Benefit Assessment
Oral Truvada for PrEP has been FDA approved since 2012. At this time, there is plentiful 
evidence to support the use of daily oral FTC/TDF in HIV-1-uninfected heterosexual biological men and women, and men who have sex with men for HIV prevention [12]. The toxicity and tolerability of daily oral FTC/TDF in HIV-uninfected individuals have been established. Side effects that may arise in the first weeks of PrEP use -- nausea, abdominal crampi[INVESTIGATOR_007], vomiting, dizziness, headache, and fatigue usually go away without treatment interruption (see Truvada Prescribing information for more details). Known potential risks can be effectively managed by [CONTACT_82963]. Participants enrolled in this study will be provided Truvada for PrEP within the confines of an established PrEP clinic, and will benefit from the expertise of trained staff.  Individuals who may be susceptible to the possible nephrotoxic effect of FTC/TDF as determined by [CONTACT_82964] (see exclusion criteria) will not be enrolled in the study. Long term effect of Truvada use (such as bone density loss or kidney dysfunction) are unlikely to occur over the course of this short study in otherwise healthy participants [13-15].  Participants will be seen weekly by a clinician, and any adverse event immediately addressed, in addition participants will be interacting daily with study staff via phone, providing an opportunity to address any questions or concerns. Moreover, the daily interactions with study staff will provide support for adherence. Concerns about risks of combining gender-affirming hormone therapy and PrEP will be alleviated by [CONTACT_82965] M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 20 of 45
Protocol Template Effective: 07 JAN 2015 therapy. Guidelines for these matters will be provided by [CONTACT_82966] (CoE-T).
4 STUDY OBJECTIVES4.1 Primary Objective
To assess pharmacokinetics for daily oral FTC/TDF in transgender women and 
transgender men, and to determine if FTC/TDF drug concentrations are lower among transgender women who are using hormone therapy and in transgender men who use testosterone compared to historical controls in non-transgender MSM.
4.2 Secondary Objectives
To determine if daily oral FTC/TDF is associated with comparable rates of adverse events 
(AEs) in transgender women and in transgender men compared to historical controls in non-transgender MSM.
5 STUDY DESIGN5.1 Study Overview
This is a single center pharmacokinetic study of daily oral Truvada at the following FDA 
approved dose of one tablet containing 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF) for PrEP using daily directly observed therapy (DOT). 
The study will include 48 participants will be divided into two groups: one group will 
include 24 participants who currently describe their gender identity as “woman” or “transgender women”, or other transfeminine spectrum identity, and the second group will enroll 24 participants who identify as “man” or “transgender man”, or other transmasculine spectrum identity. 
Each participant will be taking a single daily dose of study drug in DOT performed either 
via video calling, or at study visit, for a total study duration of 28 to 30 days (4 weeks).
Laboratory evaluations for HT (including testosterone, or estradiol) drug levels will be 
performed at enrolment, and after 4 weeks on study drug. Study drug levels will be monitored weekly in DBS while participants are on study.
Screening data will be reviewed to determine participant eligibility.  Participants who 
meet all inclusion criteria and none of the exclusion criteria will be entered into the study. 
The treatment regimen that will be used:
••Truvada at the following FDA approved dose of one tablet containing 200 mg of 
emtricitabine and 300 mg of tenofovir disoproxil fumarate
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 21 of 45
Protocol Template Effective: 07 JAN 2015 Total duration of participant participation will be up to 4 weeks, plus the 28 days of 
screening window period between screening visit and on study daily observed therapy.  Total duration of the study is expected to be 9 -10 months.
5.2 Pharmacogenetic testing
Pharmacogenetics (PGx) studies the variability in drug response due to hereditary factors 
in populations. There is increasing evidence that individual’s genetic background may impact the pharmacokinetics (absorption, distribution, metabolism and elimination) of drugs. The goal of the PGx analyses is to investigate a relationship between genetic factors and PK measures in I-BrEATHe, for example if there is potential unexpected or unexplained variation in drug levels. Blood samples collected for drug levels on DBS may be used for DNA extraction and PGx assessments. Participants will be specifically asked if they wish to participate in the genetic testing in the informed consent form.
6 CRITERIA FOR EVALUATION6.1 Primary Endpoint
The primary endpoints for this study are the pharmacokinetics measures. These PK 
analyses are dependent on adherence and will be assessed at the end of study completion.
6.2 Secondary Endpoints
N/A
6.3 Safety Evaluations
AEs: Grade [ADDRESS_90500] may be recruited to participate in this sub study, however the I-BrEATHe sub study may also enroll volunteers outside of the TRIUMH study.  
Up to 48 volunteers who meet the inclusion and exclusion criteria will be eligible for 
participation.  
7.2 Inclusion Criteria:
All subjects:
•HIV antibody seronegative (negative HIV rapid test),
•18 years or older,
•Has a smart phone with access to two-way video call capability,
•Willingness to be contact[CONTACT_5365] a short call every day for 4 weeks,
•Adequate renal function (creatinine clearance ≥ 60 ml/min estimated by [CONTACT_82967]), 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 22 of 45
Protocol Template Effective: 07 JAN 2015 •Provides written informed consent,
For Transgender women:
•Male assigned sex at birth, and self-reported current gender identity as “woman” 
or “transgender women”, or other trans-feminine spectrum identity, 
•Current feminizing Hormone Therapy (HT) use for at least 6 months,
For Transgender men:
•Female assigned sex at birth, and self-reported current gender identity as “man” or 
“transgender man”, or other trans-masculine spectrum identity,
•Current masculinizing Hormone Therapy (HT) use for at least 6 months with 
testosterone 
7.3 Exclusion Criteria
•Expects to change or discontinue current HT use during the 4 weeks study period,
•Signs of symptoms of acute viral syndrome,
•Use of FTC or TDF in the past 90 days
•Receiving ongoing therapy with any of the following:
ART, including nucleoside analogs, non-nucleoside reverse transcriptase 
inhibitors, protease inhibitors or investigational antiretroviral agents interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, systemic chemotherapeutic agents, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agents
•Renal insufficiency documented as Creatinine Clearance < 60 ml/min
•For masculine-spectrum identifying persons, positive pregnancy test at screening
•At enrollment, has any other condition or factor that, based on the opi[INVESTIGATOR_82948], would preclude provision of informed consent; make participation in the study unsafe; complicate interpretation of study outcome data; or otherwise interfere with achieving the study objectives.
7.[ADDRESS_90501] be performed and reviewed within 28 days of initiating the screening process and all screen results available prior to enrolment. If all inclusion criteria are met, and participant 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 23 of 45
Protocol Template Effective: [ADDRESS_90502] a reception area or a waiting area, a physical examination room, and/or counseling room, a study storage area or pharmacy, a data management area with locked cabinets or equivalent, computer access, laboratory facilities, and/or a phlebotomy area.
7.5.2 Recruitment
The current recruitment aim for this study is 48 participants, as described in sections 5.1 and 7.1.  To reach the target enrolment number, up to 80 potential participants may be screened.
The recruitment strategies may include one or several of the following: 
•Sending a “Dear Doctor” letter to healthcare providers who have a large number of 
transgender patients and asking for provider referral, 
•Advertising the I-BrEATHe study on social media plate-forms, 
•Using principal investigators’ database of participants who were enrolled in 
studies previously conducted at the UCSF CoE-T. Volunteers in this CoE-T 
database have given consent to be contact[CONTACT_5646], 
•Asking participants who have enrolled in the main TRIUMPH study,
•Inviting USCF CoE-T staff who may be good candidates,
•Using word of mouth,
•Posting flyers in targeted areas, agencies, clinics, Community Based 
Organizations, or Triumph community mobilization activities
These approaches, along with input from our community advisory boards and our current programs that serve transgender communities, will be used in recruitment efforts. 
Volunteers interested in I-BrEATHe will be able to contact a special phone number 
created especially for the study. Callers to this number will be routed to the study team. If a study staff member is unable to answer the phone, there will be an outgoing message which will allow leaving a voicemail for a call back, as well as information on clinic drop-in hours for those with unreliable phone service. Study team members may also be available at community mobilization activities to recruit. Efforts will be made to pre-screen inquiries by [CONTACT_648], at events, or at the referring clinics for eligibility based on inclusion criteria. Participants will then be referred to the study site for screening.
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 24 of 45
Protocol Template Effective: 07 JAN 2015 7.5.3 Retention
Given to the lack of evidence to guide trans-specific recruitment and retention strategies 
or trans-inclusive implementation practices, we will use the expertise of the CoE-T to engage with our transgender identified participants. The lack of attention to the sociocultural context of trans women’s lives especially and adaptations from other populations (i.e. MSM) have proven insufficient and unacceptable by [CONTACT_82968], evidenced by [CONTACT_82969]. Our study team has an understanding of the pervasive role of trauma in transgender people’s lives, specifically trauma that is often enacted in medical settings and can lead to the avoidance of medical care, including HIV testing and prevention. For transgender people, feeling safe and being able to trust one’s provider is a pre-requisite to successful engagement and retention in healthcare. Trust must be established within and throughout the community, as transgender social networks are tightly knit. 
Therefore, the I-BrEATHe study staff will be selected based on heightened sensitivity to 
transgender issues, appropriate training in transgender competency, and will possibly be members of the transgender communities themselves. Staff will be in close contact [CONTACT_82970]. Staff will remind participants by e-mail and/or telephone of their upcoming appointments. The participants will be interacting daily via video calls which can help create a relationship of trust. Participants will receive monetary incentive at their visit to the study site to encourage the video calls participations during the previous week. These incentives will be reviewed by [CONTACT_82971]. At the end of the study, the participants may be invited to an appreciation event.
[ADDRESS_90503] therapy is allowed except for treatments noted in the exclusion criteria described 
above and as noted in the prohibited medications section below.  
8.2 Prohibited Medications and Treatments
The following medications are prohibited during the study and administration will be 
considered a protocol violation:
ART, including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, 
protease inhibitors or investigational antiretroviral agents, interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, systemic chemotherapeutic agents, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agents
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 25 of 45
Protocol Template Effective: [ADDRESS_90504] for female assigned at birth transmasculine people, when appropriate (see study procedures below).
9.2 FTC/TDF
9.2.1 FTC/TDF Formulation
FTC/TDF is a fixed-dose co-formulation of FTC and TDF disproxil fumarate (TDF). Each 
FTC/TDF tablet contains of 200 mg of FTC and 300 mg of TDF (equivalent to 245 mg of tenofovir disoproxil). Please refer to the full prescribing information for FTC/TDF for more information regarding drug information, side effects, and storage conditions. The Truvada pi[INVESTIGATOR_82949] a blue oblong pi[INVESTIGATOR_82950]. 
9.2.2 FTC/TDF and pregnancy
FTC/TDF is categorized as pregnancy category B by [CONTACT_1622].  For the study population 
assigned male at birth, the risks to pregnancy will be limited. For the population assigned female at birth, risks associated with pregnancy will be shared, and a positive pregnancy test at enrolment will be an exclusion criterion.  Study participants will be counselled that study drug should not be shared with any individual.  
9.2.[ADDRESS_90505] from humidity and polyester packing material that cushions it during handling and shippi[INVESTIGATOR_007].  [COMPANY_009] will prepare bottles of study agent that are each labeled with the active agents, the expi[INVESTIGATOR_82951]. Each bottle will be assigned the participant’s individual identification number or PID at the site for tracking purposes.
9.3 Supply of Study Drug at the Site
[COMPANY_009] will ship Study Drug to the investigational site at study start up.  The initial study 
drug shipment will be shipped after site activation (i.e., all required regulatory documentation has been received and approved by [CONTACT_82972], and the study is ready to begin). Subsequent study drug shipments will be made after site request for resupply. Replacement study drug will be shipped at the investigator’s request.
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 26 of 45
Protocol Template Effective: 07 JAN 2015 9.3.1 Storage
The study drug will be stored in accordance with the drug manufacturer’s 
recommendations. Storage area will be locked by a secure door.  The study area and storage facility will have climate-controlled environments, with temperature to remain within limits allowed by [CONTACT_82973]. The drug will be stored at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Drug will be stored away from heat, moisture, and light
. If the temperature of study drug storage in the 
clinic/pharmacy exceeds or falls below this range, this should be reported to the investigators and captured as a deviation. Participants will be instructed to store the medication in original packaging (bottle and protected from light) at room temperature according to the instructions outlined on the drug packaged insert.
9.4 Dispensation of Study Drug at the Site
9.4.1 Dosage/Dosage Regimen
The treatment is FTC/TDF orally once daily via DOT, with or without food for a duration of 28 days. Optimal timing between doses is 24 hours. 
9.4.2 Dispensing
Study clinicians (PrEP clinician, or Research Nurse Practitioner, or physician) or nurses will be responsible for dispensing study medication to participants. Only participants who meet enrolment criteria will be dispensed study medication. Upon study drug dispensation, the study staff  will document dispensation and date of dispensation in a Drug Dispensation 
Log. 
9.4.[ADDRESS_90506] 60 seconds in duration and will be focused on watching the FTC/TDF tablet be placed into the mouth, swallowed, and the mouth opened to verify the table is no longer present. Before the table is ingested, the participant will be asked a question about food ingestion in the prior hour or intent to eat in the next hour.
Participant are encouraged not to take the study drug outside of the video call setting. 
However, if participant cannot perform a video call for the DOT (no Wi-Fi, cell phone dies…), the pi[INVESTIGATOR_82952], or back up documentation of the pi[INVESTIGATOR_82953]. The time stamped video will be shared with study team at the next visit. In last resort, if none of these options are possible, a simple text such as “Hi study clinician’s name , dosing at hh.mm on 
dd-mmm, Thanks” could be sent to the team. If the daily DOT call is not documented, it will be considered a missed dose.
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 27 of 45
Protocol Template Effective: [ADDRESS_90507] the study medication, replacement will be allowed once.
9.6 Measures of Treatment Adherence
Daily adherence will be directly observed by [CONTACT_82974], or witnessed by [CONTACT_82975].  Study staff will monitor the FTC/TDF tablet be placed into the mouth, swallowed, and the mouth opened to verify the table is no longer present.  Alternate documentations of pi[INVESTIGATOR_82954] 9.4.[ADDRESS_90508] (HIPAA) authorization will be signed and dated by [CONTACT_82976]’s legal representative.
10.1 Clinical Assessments
10.1.1 Concomitant Medications
All concomitant medication and concurrent therapi[INVESTIGATOR_82955], 
Enrolment, weeks 1, 2, 3 and 4, and at early termination when applicable.  Dose, route, 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 28 of 45
Protocol Template Effective: 07 JAN 2015 unit frequency of administration, and indication for administration and dates of 
medication will be captured in a Concomitant Medications Log.
10.1.2 Demographics 
Demographic information (i.e. age, birth assigned sex, gender identity, race, ethnicity, education, employment…) will be recorded at screening.
10.1.3 Medical History 
Relevant medical history, including history of current disease, other pertinent history, and information regarding underlying diseases will be recorded at Screening.
10.1.4 Physical Examination
Qualified clinician (Research Nurse Practitioner, or physician) or nurse will complete a brief targeted physical exam at enrolment, including weight and height.  Abnormal physical exam findings must be documented and will be followed by a physician or other qualified staff at the next scheduled visit. Special attention will be given to signs of symptoms of acute viral infection.
10.1.[ADDRESS_90509] (SFDPH HIV Surveillance Unit phone #: 415/554-9050) or other equivalent program for participants outside of SF. Cases must be reported within 7 days to the Health Officer or other equivalent program for community resources provision and to initiate HIV care. Study team will ensure that participant is linked to care.  
10.1.7 Counselling around daily DOT
At screening, at enrolment, when initial study drug is dispensed, and at every weekly visit when the blood is drawn for DBS, participants will meet briefly with their study clinician or nurse, to remind participant to the importance of participating in the daily DOT for the success of the pharmacokinetic study
10.1.8 Adverse Events
Information regarding occurrence of adverse events will be captured throughout the study. Duration (start and stop dates), severity/grade, outcome, treatment and relation to study drug will be recorded via interviewer administered symptoms and side effects questionnaires and on an AE log, as appropriate. Study participants can also prompt study team during daily video calls to potential concerns, and these concerns may be addressed on a return phone call or at next visit by a clinician or a nurse.
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 29 of 45
Protocol Template Effective: [ADDRESS_90510] at enrolment, unless they affidavit that they are engaging in NO sexual activity with anyone with a penis, and/or have no ovaries and/or uterus.
10.2 Clinical Laboratory Measurements 
10.2.1 Blood Chemistry Profile
Blood will be obtained for determination of creatinine, and creatinine clearance estimated 
by [CONTACT_82961], alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubine. 
10.2.2 Kidney function Profile
Urine and blood will be obtained for kidney function biomarkers measurements, including, but not limited to, uromoduline and cystatin C, at enrolment and every on-study visit week.
10.2.3 Hormonal Therapy Profile
At screening, hormone levels may be extracted from participant’s existing health records, from referring clinic or physician. 
10.2.4 Serology testing
Hepatitis B immunity status will be either documented from other reliable sources proving previous testing (health records, referring provider) or blood may be used for Hepatitis B Surface Antigen testing as part of the PrEP delivery standard of care at the study site. This testing will be done as an off protocol testing, see 10.2.4. 
10.2.[ADDRESS_90511] a series of testing related to HIV seroconversion (viral load, genotype, western blot …) if a participant is suspected of HIV acquisition.
10.2.6 Off protocol testing
If the need occurs to answer specific questions critical to study participant’s well-being in the I-BrEATHe study, at the discretion of the clinician, participant may have additional tests performed at the study site clinic or be referred to his or her physician for further laboratory testing. 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 30 of 45
Protocol Template Effective: [ADDRESS_90512] been demonstrated to be suitable for monitoring active drug metabolites concentrations among PrEP users in iPrEx OLE. Analysis of the active phosphorylated moieties of tenofovir has a large dynamic range, capable of detecting as little as 2 tablets per month. DBS will be processed in accordance with procedures developed for the iPrEx OLE study [9]. 
10.3.2 Hormonal Therapy Profile
Blood will be drawn at enrolment and at study exit for quantification of estradiol, and total and free testosterone levels, as well as sex hormone binding globulin (SHBG) and dihydrotestosterone (DHT) using Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) and/or equilibrium dialysis. These measures will be used for the outcome analyses. 
10.3.[ADDRESS_90513] resort, if none of these options are possible, a simple text such as “Hi study clinician’s name , dosing at hh.mm on dd-
mmm, Thanks” could be sent. Study personnel will use the Drug Dispensation, Hormones and DOT (DDHD) Log to document directly observed doses. Participants will be given a detailed calendar that shows scheduled dosing days. This schedule will also be reinforced when study personnel interact with participants. The video assessments will last approximately 1 minute and study personnel will not discuss study details for privacy reasons. General study questions will be discussed, such as, “how do you feel”, “do you have any concerns”, etc. In this way, adverse events may be monitored on all dose witnessing days.  During the video assessment, staff will confirm with study participant uptake of HT, which may or may not be directly observed.
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 31 of 45
Protocol Template Effective: 07 JAN 2015 11 EVALUATIONS BY [CONTACT_16990]
11.1 Phone or referring clinic pre screening
A number of questions will be asked from potential participants over the phone, at 
recruiting events or at the referring provider’s clinic, to prescreen volunteers. These questions include capability to do two-ways daily video call, ability to go to the study site weekly for blood draws, gender identity, and current trans hormone therapy.
11.2 Visit 1 (Screening visit)
1. Review the study with the participant (or participant’s legal representative) and 
obtain written informed consent and HIPAA authorization, if applicable.
2. Assign the participant a unique screening number. The screen number will be the 
Participant ID or PID for the duration of the study if enrolled.
3. Record demographics data.
4. Record brief targeted medical history, including a history of diseases, diagnosis 
date, and prior treatments.
5. Record concomitant medications.6. Perform and record vital signs.7. Conduct the drug and alcohol use scales 8. Collect blood for clinical laboratory tests (chemistry and serology, as applicable). If 
hormone levels and/or serology are available from participant’s regular health 
management, collect from existing records.
9. Collect blood for HIV rapid test, perform test and provide results.
10. If HIV rapid test is negative, and inclusion criteria are met, tentatively schedule 
participant for Visit 2 (week 0).
11. Provide visit reimbursement.
11.3 Visit 2 (week 0 or enrolment, within 28 days of screening)
1. Review results from screening visit tests with participant 
2. Concomitant medications review.3. Perform and record vital signs, including weight and height.4. Perform brief targeted physical exam, which includes an assessment of signs and 
symptoms of an acute viral syndrome, including fever, pharyngitis, rash, myalgias, 
arthralgias, diarrhea, or headache.  
5. Perform and record blood HIV rapid testing
6. If female assigned at birth, perform pregnancy test as indicated7. Confirm eligibility8. Draw blood for hormone levels, DBS, kidney function9. Collect urine for kidney function markers
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 32 of 45
Protocol Template Effective: [ADDRESS_90514] study medication bottle number on the Drug Dispensation Log13. Review importance of study procedures (DOT/weekly visit), using client centered 
counselling for adherence
14. Coordinate video calling schedule with participant and provide calendar of calls15. Provide visit reimbursement.
11.4 Visit 3 (Week 1, 2 and 3, visit window plus or minus 2 days)
1. Record any Adverse Experiences, using PrEP and a hormones specific symptoms 
and side effects questionnaires, and the AE log
2. Assessment for acute viral infection3. Review participant daily observed therapy log, discuss adherence challenges if any, 
provide support if necessary for DOT. 
4. Ask about potential substance use5. Record changes to concomitant medications6. Draw blood for DBS and kidney function markers7. Collect urine for kidney function markers8. Provide visit reimbursement
11.5 Visit 4 (Week 4 or end of study, visit window plus or minus 2 days)
1. Record any Adverse Experiences (including the symptoms and side effects 
questionnaires) and review participant daily observed therapy log
2. Ask about potential substance use3. Record changes to concomitant medications.4. Perform vital signs, including height and weight5. Asses for symptoms of acute viral infection6. Collect blood for chemistries, HIV rapid testing, hormone levels, and kidney 
function markers as well as for DBS
7. Collect urine for kidney function biomarkers8. Collect all unused study drug.9. Provide visit reimbursement10. Thanks participant for participation11. Referral to a clinical PrEP service if the participant chooses to continue PrEP
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 33 of 45
Protocol Template Effective: [ADDRESS_90515] urine for kidney function biomarkers10. Provide visit reimbursement11. Thanks participant for participation 12. Referral to a clinical PrEP service if the participant chooses to continue PrEP.
12 ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION12.1 Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical investigation of a 
patient administered a pharmaceutical product and that does not necessarily have a causal relationship with the treatment.  An AE is therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the administration of an investigational product, whether or not related to that investigational product.  An unexpected AE is one of a type not identified in nature, severity, or frequency in the current Investigator’s Brochure or of greater severity or frequency than expected based on the information in the Investigator’s Brochure.
The Investigator will probe, via discussion with the participant, for the occurrence of AEs 
during each participant visit and record the information in the site’s source documents.  Adverse events will be recorded in the patient chart, in an AE log and/or CRF.  Adverse events will be described by [CONTACT_24109] (start and stop dates and times), severity, outcome, treatment and relation to study drug, or if unrelated, the cause.
A side effect structured questionnaire will be used to track AE.AE SeverityThe U.S. Department of Health and Human Services, National Institutes of Health, 
National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0. [November 2014] should be used to assess and grade AE severity, including laboratory abnormalities judged to be clinically significant.  The guidelines shown in 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 34 of 45
Protocol Template Effective: 07 JAN 2015 Table 1 below should be used to grade severity.  It should be pointed out that the term 
“severe” is a measure of intensity and that a severe AE is not necessarily serious.
Table 1.  AE Severity Grading
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE-
THREATENING
Clinical adverse
event  NOT 
identified 
elsewhere in the
grading tableMild symptoms
c
ausing no or 
minimal interference 
with usual social &
functional activities 
with intervention not indicatedModerate symptoms
causing greater than 
minimal interference with usual social &
functional activities 
with intervention indicatedSevere symptoms
causing inability to 
perform usual social & functional activities with
intervention or 
hospi[INVESTIGATOR_82956]-threatening
symptoms causing inability to 
perform basic self-care functions with intervention
indicated to prevent 
permanent impairment, persistent disability, or death
AE Relationship to Study Drug
The relationship of an AE to the study drug should be assessed using the following the 
guidelines in Table 2.
Table 2.  AE Relationship to Study Drug
Relationship
to DrugComment
Definitely Previously known toxicity of agent; or an event that follows a reasonable temporal 
sequence from administration of the drug; that follows a known or expected response 
pattern to the suspected drug; that is confirmed by [CONTACT_13635][INVESTIGATOR_11125]; and that is not explained by [CONTACT_41846].
Probably An event that follows a reasonable temporal sequence from administration of the drug; that follows a known or expected response pattern to the suspected drug; that is confirmed by [CONTACT_13635][INVESTIGATOR_11125]; and that is unlikely to be explained by [CONTACT_82977]’s clinical state or by [CONTACT_82978].
Possibly An event that follows a reasonable temporal sequence from administration of the drug; that follows a known or expected response pattern to that suspected drug; but that could readily have been produced by a number of other factors.
Unrelated An event that can be determined with certainty to have no relationship to the study 
drug.
12.2 Serious Adverse Experiences (SAE)
An SAE is defined as any AE occurring at any dose that results in any of the following 
outcomes:
•death
•a life-threatening adverse experience
•inpatient hospi[INVESTIGATOR_1081]
•a persistent or significant disability/incapacity
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 35 of 45
Protocol Template Effective: 07 JAN 2015 ••a congenital anomaly/birth defect 
Other important medical events may also be considered an SAE when, based on 
appropriate medical judgment, they jeopardize the participant or require intervention to prevent one of the outcomes listed. 
12.2.1 Serious Adverse Experience Reporting
Study sites will document all SAEs that occur (whether or not related to study drug) per 
UCSF CHR Guidelines .  The collection period for all SAEs will begin after informed 
consent is obtained and end after procedures for the final study visit have been completed.
In accordance with the standard operating procedures and policies of the local Institutional 
Review Board (IRB), the site investigator will report SAEs to the IRB.  
12.2.2 Suicidal ideation
Suicidal ideation-related events will be reported to the IRB as indicated by [CONTACT_82979], Version 2.0. [November 2014] described above. In addition, participants will be offered support and access to mental health services available at the study site. Study staff will ensure study participants are linked to care.
12.[ADDRESS_90516]. Robert Grant should be contact[CONTACT_82980].
Phone: [PHONE_1943]  
13 DISCONTINUATION AND REPLACEMENT OF PARTICIPANTS
13.1 Early Discontinuation of Study Drug 
A participant may be discontinued from study treatment at any time if the participant, or 
the investigator, feels that it is not in the participant’s best interest to continue.  The following is a non-exclusive list of possible reasons for study treatment discontinuation: 
•Participant withdrawal of consent
•Participant is not adhering with study procedures
•Adverse event that in the opi[INVESTIGATOR_82957]
•Protocol violation requiring discontinuation of study treatment; including change or 
interruption of the HT regimen
•Lost to follow-up
•Sponsor request for early termination of study
•Positive pregnancy test (performed outside of the study settings)
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 36 of 45
Protocol Template Effective: 07 JAN 2015 If a participant is withdrawn from treatment due to an adverse event, the participant will 
be referred to care.
All participants who discontinue study treatment will be withdrawn from the study and 
every effort will be made to welcome participant for an early withdrawal visit as soon as possible at which the procedures listed in section 10.5 should be performed.  At this visit, reasons for stoppi[INVESTIGATOR_82958], if participant is willing to share.
All participants are free to withdraw from participation at any time, for any reason, 
specified or unspecified, and without prejudice.
Reasonable attempts will be made by [CONTACT_29170] a reason for participant 
withdrawals.  The reason for the participant’s withdrawal from the study will be specified in the participant’s source documents Refer to Section 10.5 for early termination procedures.
12.3 Withdrawal of Participants from the Study
A participant may be withdrawn from the study at any time if the participant, or the 
investigator feels that it is not in the participant’s best interest to continue.  
All participants are free to withdraw from participation at any time, for any reason, 
specified or unspecified, and without prejudice.
Reasonable attempts will be made by [CONTACT_29170] a reason for participant 
withdrawals.  The reason for the participant’s withdrawal from the study will be specified in the participant’s source documents.  As noted above, participants who discontinue study treatment early (i.e., they withdraw prior to week 4) should have an early withdrawal visit. Refer to Section 10.5 for early termination procedures.  Participants who withdraw after week 0 but prior to week 1 should be encouraged to come in for a withdrawal visit.  
12.4 Replacement of Participants
Participants who withdraw from the study treatment may be replaced.  
14 PROTOCOL VIOLATIONS
A protocol violation occurs when the participant, or investigator fails to adhere to 
significant protocol requirements affecting the inclusion, exclusion, participant safety and primary endpoint criteria.  Protocol violations for this study include, but are not limited to, 
the following:
••Failure to meet inclusion/exclusion criteria
•Use of a prohibited concomitant medication
•Failure to adhere to study drug regimen
•Failure to participate in the daily directly observed therapy (2 or more failed calls with 
no back up documentation of pi[INVESTIGATOR_82959])
•Change or interruption of HT regimen 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 37 of 45
Protocol Template Effective: 07 JAN 2015 ••Failure to comply with Good Clinical Practice (GCP) guidelines will also result in a 
protocol violation. The Sponsor, in this case the principal investigators, will determine 
if a protocol violation will result in withdrawal of a participant.
When a protocol violation occurs, it will be discussed with the investigator and a Protocol Violation Form detailing the violation will be generated and submitted to the IRB. A copy of the form will be filed in the site’s regulatory binder.
15 STATISTICAL METHODS AND CONSIDERATIONS
Prior to the analysis of the final study data, a detailed Statistical Analysis Plan (SAP) will 
be written describing all analyses that will be performed.  The SAP will contain any modifications to the analysis plan described below.  
15.1 Data Sets Analyzed
All eligible and dosed participants who are enrolled into the study and receive all doses of 
the study drug will be included in the pharmacokinetic analysis.
15.2 Demographic and Baseline Characteristics
The following demographic variables at screening will be summarized: race, ethnicity, 
age, gender identity, birth sex. 
15.3 Analysis of Primary Endpoint
We will compare levels of TFV-DP in dried blood spots and rates of adverse events 
between trans men and trans women and a group of MSM historical controls from the iPrEx OLE study.  We will compare log transformed TFV-DP levels using a linear mixed effects model with factors for group (trans men v. trans women v. MSM) and times (1, 2, 3 and 4 weeks after initiation) and their interaction with an unstructured covariance across visits and test for differences at between groups at each time point. If values appear to violate the normal distribution, we will obtain p-values and confidence intervals using the bootstrap. All p-values will be two-sided with p-value < 0.[ADDRESS_90517].
Adverse event rates will be coded by [CONTACT_82981].  Adverse events will be tabulated and will include the number of patients for whom the event occurred, the rate of occurrence, and the severity and relationship to study drug.  
15.4 Sample Size 
A sample size of 48 (24 trans women and 24 trans men) allows detection of a difference of 
0.52 log difference (1.68 fold difference) in TFV-DP from dried blood spots with 81% power on a two-sided 0.[ADDRESS_90518] at any time point between our trans participants and MSM historical controls. A difference of 0.70 log (2.0 fold difference) can be detected between either group (trans men or women) and MSM historical controls with 80% power on a two-sided 0.[ADDRESS_90519]. This is sufficient to determine if the differences in drug 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 38 of 45
Protocol Template Effective: [ADDRESS_90520] all observations and other pertinent data for each participant treated with the study drug.  
Study personnel at study site will enter data from source documents corresponding to a 
participant’s visit into the protocol-specific database when the information corresponding to that visit is available.  Participants will not be identified by [CONTACT_82982], but will be identified by a site number, participant identification number (PID).
For paper source documents:  If a correction is made on a CRF, the study staff member 
will line through the incorrect data, write in the correct data and initial and date the change.
The Investigator is responsible for all information collected on participants enrolled in this 
study.  All data collected during the course of this study must be reviewed and verified for completeness and accuracy by [CONTACT_82983].  A copy of the CRF and/or source documents will remain at the Investigator’s site at the completion of the study for a period of [ADDRESS_90521] unauthorized access by [CONTACT_82984]; appropriate backup copi[INVESTIGATOR_1493].  Databases are backed up by [CONTACT_82985].  
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 39 of 45
Protocol Template Effective: 07 JAN 2015 At critical junctures of the protocol (e.g., production of interim reports and final reports), 
data for analysis is locked and cleaned per established procedures.
16.[ADDRESS_90522] make study data accessible to the monitor, other authorized 
representatives of funding agencies, IRB/IEC, and Regulatory Agency (e.g., FDA) inspectors upon request. For each participant, the signed Informed Consent, HIPAA Authorization and copi[INVESTIGATOR_82960]. Data will be kept separate from documents containing personal identifiers.  The Investigator must ensure the reliability and availability of source documents from which the information in the database was derived.
All study documents (patient files, signed informed consent forms, copi[INVESTIGATOR_3110], Study 
File Notebook, source logs and check lists, etc.) must be kept secured for a period of 2 years following study results analysis is done.
16.6 Monitoring
Monitoring visits at the study site may be conducted by [CONTACT_82986] U.S. CFR Title 21 Parts 50, 56, and 312 and ICH Guidelines for GCP (E6).  By [CONTACT_12570], the investigators grant permission to the appropriate regulatory authorities to conduct on-site monitoring and/or auditing of all appropriate study documentation.
16.7 Participant Confidentiality
In order to maintain participant confidentiality, only a PID (personal identifying number) 
will identify all study participants on CRFs and other documentation, specimens send for testing on site or at remote laboratories and with the data sent to data management team for analyses. Some information may be extracted from existing medical charts, in the case of hormonal therapy for referred participants, for example; in this case, data will be transferred to the I-BrEATHe study document and participant’s chart, associated with his or her PID and no personal identifiers. For the video calling, every effort will be made to protect the privacy or participants. Video conference platforms that encrypt data, password protection and study specific phone will be used. Privacy for video-dosing will be stressed by [CONTACT_3462], and all meetings will occur in a mutually agreed upon location. Study details will not be discussed by [CONTACT_82987], unless at participant’s specific request. These procedures and risks will be described in the informed consent document.
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS
The study will be conducted according to the Declaration of Helsinki, Protection of 
Human Volunteers (21 CFR 50), Institutional Review Boards (21 CFR 56), and Obligations of Clinical Investigators (21 CFR 312).
To maintain confidentiality, all laboratory specimens, CRFs, logs, reports and other source 
records, as well as the results database will be identified by a coded PID only.  All study 
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 40 of 45
Protocol Template Effective: 07 JAN 2015 records will be kept in a locked file cabinet and informed consent forms linking a patient’s 
name [CONTACT_1639] a patient identification number will be stored separately in another locked file cabinet.  Clinical information will not be released without documented permission of the participant, except as necessary for monitoring by [CONTACT_1622].  The Investigator must also comply with all applicable privacy regulations (e.g., Health Insurance Portability and Accountability Act of 1996, EU Data Protection Directive 95/46/EC).
17.1 Protocol Amendments
Any amendment to the protocol will be written by [CONTACT_473], who are the sponsors 
for this study.  Protocol amendments cannot be implemented without prior written IRB/IEC approval except as necessary to eliminate immediate safety hazards to patients.  A protocol amendment intended to eliminate an apparent immediate hazard to patients may be implemented immediately, provided the IRBs are notified within five working days.
17.2 Institutional Review Boards and Independent Ethics Committees
The protocol and consent form will be reviewed and approved by [CONTACT_1201]/IEC of the 
participating center prior to study initiation.  Serious adverse experiences regardless of causality will be reported to the IRB/IEC in accordance with the standard operating procedures and policies of the IRB/IEC, and the Investigator will keep the IRB/IEC informed as to the progress of the study.  The Investigator will obtain assurance of IRB/IEC compliance with regulations.
Any documents that the IRB/IEC may need to fulfill its responsibilities (such as protocol, 
protocol amendments, consent forms, information concerning patient recruitment, payment or compensation procedures, or other pertinent information) will be submitted to the IRB/IEC.  The IRB/IECs written unconditional approval of the study protocol and the informed consent form will be in the possession of the Investigator before the study is initiated.  The IRB/IECs unconditional approval statement will be transmitted by [CONTACT_82988].  This approval must refer to the study by [CONTACT_82989].
Protocol and/or informed consent modifications or changes may not be initiated without 
prior written IRB/IEC approval except when necessary to eliminate immediate hazards to the patients or when the change(s) involves only logistical or administrative aspects of the study.  Such modifications will be submitted to the IRB/IEC and written verification that the modification was submitted and subsequently approved should be obtained.  
The IRB/IEC must be informed of revisions to other documents originally submitted for 
review; serious and/or unexpected adverse experiences occurring during the study in accordance with the standard operating procedures and policies of the IRB; new information that may affect adversely the safety of the patients of the conduct of the study; an annual update and/or request for re-approval; and when the study has been completed.
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 41 of 45
Protocol Template Effective: 07 JAN 2015 17.3 Informed Consent Form 
Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH 
GCP, US Code of Federal Regulations for Protection of Human Participants (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 56, Subpart A), the Health Insurance Portability and Accountability Act (HIPAA, if applicable), and local regulations.
The Investigator will prepare the informed consent form, and research HIPAA 
authorization form. Investigators will provide the documents to submission to the IRB/IEC.  The consent form generated by [CONTACT_82990]/IEC.  The written consent document will embody the elements of informed consent as described in the International Conference on Harmonisation and will also comply with local regulations. The Investigator will keep an IRB/IEC-approved copy of the Informed Consent Form for the study file.
A properly executed, written, informed consent will be obtained from each participant 
prior to entering the participant into the study.  Information should be given in both oral and written form and participants (or their legal representatives) must be given ample opportunity to inquire about details of the study.  If a participant is unable to sign the informed consent form (ICF) and the HIPAA authorization, a legal representative may sign for the participant.   A copy of the signed consent form will be given to the participant or legal representative of the participant and the original will be maintained with the participant’s records.
17.[ADDRESS_90523] of 1996. 
17.5 Investigator Responsibilities
By [CONTACT_29184], the Investigator agrees to:
1. Conduct the study in accordance with the protocol and only make changes after 
notifying the IRB, except when to protect the safety, rights or welfare of participants.
2. Personally conduct or supervise the study.3. Ensure that the requirements relating to obtaining informed consent and IRB review 
and approval meet federal guidelines, as stated in § 21 CFR, parts 50 and 56.
4. Report any AEs that occur in the course of the study, in accordance with §[ADDRESS_90524] of the 
study are informed about their obligations in meeting the above commitments.
6. Maintain adequate and accurate records in accordance with §21 CFR 312.62 and to 
make those records available for inspection with the Sponsor (or designee).
 Robert M Grant and Madeline DeutschConfidential
Version #:1.3 Version Date: 15-Mar-2018 Page 42 of 45
Protocol Template Effective: 07 JAN 2015 7. Ensure that an IRB that complies with the requirements of §21 CFR part 56 will be 
responsible for initial and continuing review and approval of the clinical study.
8. Promptly report to the IRB all changes in the research activity and all unanticipated 
problems involving risks to participants or others (to include amendments and IND 
safety reports).
9. Seek IRB approval before any changes are made in the research study, except when 
necessary to eliminate hazards to the patients/participants.
10. Comply with all other requirements regarding the obligations of clinical investigators 
and all other pertinent requirements listed in § 21 CFR part 312.
 Robert M Grant and Madeline B DeutschConfidential
Version Date: 15-Mar-2018 Page 43 of 45APPENDIX 1.  SCHEDULE OF STUDY VISITS
VISIT 1
(Screen)VISIT 2
(Week 0/enrollment) aVISIT 3
(Week 1, 2, 3)bVISIT 4
(Week 4)bVISIT 5
(Early withdrawal)
Informed Consent X
Demographics X
Medical History XX
Abbreviated Physical Exam X
Height XX X
Weight XX X
Vital Signs XX X X
HIV Rapid test XX X X
Symptoms of acute viral infection XXX X
Pharmacokinetics (DBS) XXX X
ChemistrycXX X
Kidney biomarkers (blood/urine) XXX X
Hormone Therapy levels XX X
Pregnancy Test (Urine) Xd
AUDIT and DAST scale X
Dispensing of Study Drug X
Counting of Returned Study Drug XX
Schedule DOT X
Review DOT log XXX X
Concomitant Medication Review XXXX X
Questions (PrEP, HT, drug use) XXX X
Condom distribution (optional) XXX X
Refer to PrEP program (optional) XX
a within 28 days
b ±[ADDRESS_90525], ALT, total bilirubine. Blood may be used for Hepatitis B surface antigen testing if data not available from medical chart.
d Only when indicated, see section 10.1.11 pge 27
 Robert M Grant and Madeline DeutschConfidential
Version #: 1.3 Version Date: 15-Mar-2018 Page 44 of 45
Protocol Template © CFFT TDN   Effective: [ADDRESS_90526] Sex with Men.  New England Journal of Medicine, 2010. 363(27): p. 2587-
2599.
2. Deutsch, M.B., et al., HIV pre-exposure prophylaxis in transgender women: a 
subgroup analysis of the iPrEx trial.  Lancet HIV, 2015. 2(12): p. e512-9.
3. Sevelius, J., "There's no pamphlet for the kind of sex I have": HIV-related risk 
factors and protective behaviors among transgender men who have sex with 
nontransgender men. J Assoc Nurses AIDS Care, 2009. 20(5): p. 398-410.
4. Reisner, S.L., et al., Syndemics and gender affirmation: HIV sexual risk in female-
to-male trans masculine adults reporting sexual contact [CONTACT_82991].  Int J 
STD AIDS, 2015.
5. Deutsch, M.B., et al., Electronic medical records and the transgender patient: 
recommendations from the World Professional Association for Transgender Health EMR Working Group. J Am Med Inform Assoc, 2013. 20(4): p. 700-3.
6. Escudero, D.J., et al., Inclusion of trans women in pre-exposure prophylaxis trials: 
a review.  AIDS Care, 2015. 27(5): p. 637-41.
7. Sevelius, J.M., et al., Barriers and facilitators to engagement and retention in care 
among transgender women living with human immunodeficiency virus.  Ann Behav 
Med, 2014. 47(1): p. 5-16.
8. Reisner, S.L., et al., Laboratory-confirmed HIV and sexually transmitted infection 
seropositivity and risk behavior among sexually active transgender patients at an adolescent and young adult urban community health center.  AIDS Care, 2015. 
27(8): p. 1031-6.
9. Anderson, P.L., et al., Emtricitabine-tenofovir concentrations and pre-exposure 
prophylaxis efficacy in men who have sex with men.  Sci Transl Med, 2012. 4(151): 
p. 151ra125.
10. Hendrix, C.W., et al., Dose Frequency Ranging Pharmacokinetic Study of 
Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).  AIDS Res Hum Retroviruses, 2016. 
32(1): p. 32-43.
11. Zheng, J.H., et al., Application of an intracellular assay for determination of 
tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal, 2016. 122: p. 16-20.
12. WHO Guidelines Approved by [CONTACT_82992] , in Guideline on 
When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV . 
2015, World Health Organization. Copyright (c) World Health Organization 2015.: Geneva.
13. Liu, A.Y., et al., Bone Mineral Density in HIV-Negative Men Participating in a 
Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco.  
PLoS ONE, 2011. 6(8): p. e23688.
 Robert M Grant and Madeline DeutschConfidential
Version #: 1.3 Version Date: 15-Mar-2018 Page 45 of 45
Protocol Template © CFFT TDN   Effective: 12 SEP 200714. Mulligan, K., et al., Effects of emtricitabine/tenofovir on bone mineral density in 
seronegative men from 4 continents: DEXA results of the global iPrEx study.  18th 
CROI, 2011.
15. Mulligan, K., et al., Low Bone Mass in Behaviorally HIV-Infected Young Men on 
Antiretroviral Therapy: Adolescent Trials Network (ATN) Study 021B.  Clin Infect 
Dis, 2012.